AI Article Synopsis
- High-dose atropine was studied to evaluate its effectiveness in slowing eye growth in children with Mendelian and non-Mendelian myopia, along with a mouse model of myopia.* -
- The treatment resulted in a significant reduction in the annual axial length progression compared to untreated populations, with 27% reduction in Mendelian myopes and 23% in non-Mendelian myopes.* -
- In mice, high-dose atropine also significantly reduced axial length growth, indicating the potential effectiveness of atropine across different genetic causes of myopia.*
Article Abstract
Purpose: To study the effectiveness of high-dose atropine for reducing eye growth in Mendelian myopia in children and mice.
Methods: We studied the effect of high-dose atropine in children with progressive myopia with and without a monogenetic cause. Children were matched for age and axial length (AL) in their first year of treatment. We considered annual AL progression rate as the outcome and compared rates with percentile charts of an untreated general population. We treated C57BL/6J mice featuring the myopic phenotype of Donnai-Barrow syndrome by selective inactivation of Lrp2 knock out (KO) and control mice (CTRL) daily with 1% atropine in the left eye and saline in the right eye, from postnatal days 30-56. Ocular biometry was measured using spectral-domain optical coherence tomography. Retinal dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were measured using high-performance liquid chromatography.
Results: Children with a Mendelian form of myopia had average baseline spherical equivalent (SE) -7.6 ± 2.5D and AL 25.8 ± 0.3 mm; children with non-Mendelian myopia had average SE -7.3 ± 2.9 D and AL 25.6 ± 0.9 mm. During atropine treatment, the annual AL progression rate was 0.37 ± 0.08 and 0.39 ± 0.05 mm in the Mendelian myopes and non-Mendelian myopes, respectively. Compared with progression rates of untreated general population (0.47 mm/year), atropine reduced AL progression with 27% in Mendelian myopes and 23% in non-Mendelian myopes. Atropine significantly reduced AL growth in both KO and CTRL mice (male, KO: -40 ± 15; CTRL: -42 ± 10; female, KO: -53 ± 15; CTRL: -62 ± 3 μm). The DA and DOPAC levels 2 and 24 h after atropine treatment were slightly, albeit non-significantly, elevated.
Conclusions: High-dose atropine had the same effect on AL in high myopic children with and without a known monogenetic cause. In mice featuring a severe form of Mendelian myopia, atropine reduced AL progression. This suggests that atropine can reduce myopia progression even in the presence of a strong monogenic driver.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/opo.13115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corticosteroid-induced bradycardia following high-dose methylprednisolone administration: a case report.
Ann Med Surg (Lond)
October 2024
Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Article Synopsis
- Corticosteroids, although effective in treating inflammation and modifying immune responses, can lead to several side effects like high blood sugar, hypertension, and bradycardia (slow heart rate).
- A case study details a 43-year-old woman with multiple sclerosis who developed symptomatic bradycardia after receiving high doses of methylprednisolone, which resolved after 36 hours once the medication was stopped.
- While bradyarrhythmias like bradycardia are rare compared to tachyarrhythmias, they are important to monitor, and corticosteroid-induced bradycardia typically resolves on its own and often occurs without clear reasons.
2024 RECOVER Guidelines: Advanced Life Support. Evidence and knowledge gap analysis with treatment recommendations for small animal CPR.
J Vet Emerg Crit Care (San Antonio)
June 2024
University Library, University of California, Davis, Davis, California, USA.
Objective: To systematically review the evidence and devise clinical recommendations on advanced life support (ALS) in dogs and cats and to identify critical knowledge gaps.
Design: Standardized, systematic evaluation of literature pertinent to ALS following Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Prioritized questions were each reviewed by Evidence Evaluators, and findings were reconciled by ALS Domain Chairs and Reassessment Campaign on Veterinary Resuscitation (RECOVER) Co-Chairs to arrive at treatment recommendations commensurate to quality of evidence, risk:benefit relationship, and clinical feasibility.
2024 RECOVER Guidelines: Updated treatment recommendations for CPR in dogs and cats.
J Vet Emerg Crit Care (San Antonio)
June 2024
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.
Objective: After the 2012 Reassessment Campaign on Veterinary Resuscitation (RECOVER) CPR Guidelines, this is an update of evidence-based consensus guidelines for Basic Life Support (BLS), advanced life support (ALS), and periarrest monitoring.
Design: These RECOVER CPR Guidelines were generated using a modified version of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for evidence evaluation and translation of this evidence into clear and actionable clinical instructions. Prioritized clinical questions in the Population, Intervention, Comparator, and Outcome (PICO) format were used as the basis to conduct systematic literature searches by information specialists, to extract information from relevant publications, to assess this evidence for quality, and finally to translate the findings into treatment recommendations.
Atropine sulfate as a continuous intravenous infusion for the treatment of organophosphate toxicity in a cat.
JFMS Open Rep
May 2024
Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL, USA.
Case Summary: A 1-year-old male neutered domestic shorthair cat presented on an emergency basis with clinical signs suspected to be secondary to organophosphate (OP) toxicity. The control of clinical abnormalities (bradycardia, obtundation, tachypnea, anorexia) was achieved using high-dose continuous rate intravenous infusion (CRI) of atropine sulfate (maximum rate 0.1 mg/kg/h).
View Article and Find Full Text PDFBeneficial Effects of Low-Dose Intravenous Dexmedetomidine Premedication in Patient Undergoing Laparoscopic Cholecystectomy Under General Anesthesia: A Prospective, Double-Blind, Randomized Controlled Trial.
Drug Des Devel Ther
February 2024
Department of Anesthesiology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.
Purpose: Dexmedetomidine (Dex) is a potent and highly selective α2-adrenergic receptor agonist. Within an appropriate dose range, Dex can effectively attenuate the surgical stress response, provide intraoperative hemodynamic stability, and improve the patient recovery quality. High-dose Dex can delay patient awakening from anesthesia and increase the incidence of bradycardia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!